贝伐珠单抗对肺腺癌脑转移伴难治性脑水肿患者生活质量及血清VEGF水平的影响

Effects of bevacizumab on quality of life and serum VEGF levels in patients with pulmonary adenocarcinoma with brain metastasis and refractory cerebral edema VLOG

关键词:  肺腺癌  血管内皮生长因子  难治性脑水肿  生活质量  贝伐珠单抗

Key words:  lung adenocarcinoma  VEGF  refractory cerebral edema  quality of life  bevacizumab

摘要:

[目的] 研究贝伐珠单抗对肺腺癌脑转移伴难治性脑水肿患者（归属中医肺岩伴囟填或解颅）生活质量及血清血管内皮生长因子（VEGF）水平的影响。[方法] 将从2016年1月~2019年12月我院收治的60例肺腺癌脑转移伴难治性脑水肿患者纳入研究。以随机数表法将其等分成研究组及传统组。传统组实施激素、甘露醇等传统治疗，研究组则实施贝伐珠单抗治疗。比较两组治疗前后水肿指数（EI）、生活质量以及血清VEGF水平变化情况，不良反应发生情况。[结果] 治疗后研究组及传统组EI低于治疗前，且研究组较传统组更低（均P<0.05）。治疗后研究组及传统组生活质量评分高于治疗前，且研究组较传统组更高（均P<0.05）。治疗后研究组及传统组VEGF低于治疗前，且研究组较传统组更低（均P<0.05）。研究组及传统组痰中带血、便血及蛋白尿发生率对比均不明显（均P>0.05）。研究组头痛、头晕及呕吐症状改善人数占比均高于传统组（均P<0.05）。[结论] 贝伐珠单抗可有效改善肺腺癌脑转移伴难治性脑水肿患者生活质量及VEGF，不会增大患者的不良反应相关风险。

Abstract:

[Objective] To study the effects of bevacizumab on quality of life and serum VEGF levels in patients with pulmonary adenocarcinoma with brain metastasis and refractory cerebral edema (belonging to lung rock with fontanelle filling or craniectomy).[Methods] From January 2016 to December 2019,sixty patients with lung adenocarcinoma with brain metastasis and refractory brain edema admitted to our hospital were included in the study. They were divided into research group and traditional group by random number table. The traditional group received traditional treatments such as hormone and mannitol,while the research group received bevacizumab. The changes of edema index (EI),quality of life and serum VEGF level,and the occurrence of adverse reactions were compared between the two groups before and after treatment.[Results] After treatment,EI in the research group and the traditional group was lower than that before treatment,and EI in the research group was lower than that in the traditional group (P<0.05). After treatment,the scores of life quality of the research group and the traditional group were higher than before treatment,and the scores of the research group were higher than that of the traditional group (P<0.05). After treatment,the serum VEGF level of the research group and the traditional group was lower than that before treatment,and the research group was lower than that of the traditional group (P<0.05). There was no significant difference in the incidence of blood in sputum,blood in the stool and proteinuria between the research group and the traditional group (P>0.05). The proportion of headache,dizziness and vomiting in the study group was higher than that in the traditional group (P<0.05).[Conclusion] Bevacizumab can effectively improve the quality of life and serum VEGF level of patients with lung adenocarcinoma with brain metastasis and refractory brain edema without increasing the risk of adverse reactions.